|
|
| | ENPP1 (human, recombinant) Basic information |
| | ENPP1 (human, recombinant) Chemical Properties |
| | ENPP1 (human, recombinant) Usage And Synthesis |
| Description | Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) is a type II transmembrane glycoprotein with nucleotide pyrophosphatase and phosphodiesterase enzyme activities.1 It is expressed in skeletal, adipose, hepatic, renal, cardiac, and placental tissues, as well as pancreatic islets, salivary glands, chondrocytes, fibroblasts, and lymphocytes.2 ENPP1 is a critical regulator of purinergic signaling that catalyzes the hydrolysis of ATP or GTP to AMP or GMP, respectively, as well as the hydrolysis of cGAMP, and has roles in platelet aggregation, muscle contraction, hypoxia, ischemia, cGAS-STING signaling, and cell proliferation, migration, apoptosis, and differentiation.1,3 This nucleotide hydrolysis also generates inorganic pyrophosphates, which inhibit bone and cartilage mineralization, implicating ENPP1 as a regulator of bone and cartilage development. Loss-of-function mutations in ENPP1 are associated with various calcification-related disorders, including autosomal recessive hypophosphatemic rickets type 2 (ARHR2) generalized arterial calcification of infancy (GACI), and pseudoxanthoma elasticum (PXE).1,4 ENPP1 SNPs are associated with insulin resistance and the development of diabetic nephropathy.2,5 ENPP1 hydrolysis of cGAMP in the tumor microenvironment decreases STING activation, facilitates immunosuppression, and is associated with enhanced bone metastasis in mouse xenograft models of breast cancer.1,3 Inhibition of ENPP1 promotes STING activation and increases survival in various mouse xenograft models.1 Cayman’s ENPP1 (human, recombinant) protein can be used for enzyme activity assays.WARNING This product is not for human or veterinary use. |
| | ENPP1 (human, recombinant) Preparation Products And Raw materials |
|